11 r/r CD19-positive B-ALL patients, aged from 20 to 55 years, who had not previously received CAR-T therapy, signed a written informed consent between December 2018 and June 2020 and were enrolled into the present trial in the Nanjing Drum Tower Hospital. Here, CD19 is linked to acute lymphoblastic leukemia.